|1.||Mimoz, Olivier: 3 articles (06/2013 - 01/2012)|
|2.||Petitjean, Olivier: 2 articles (06/2013 - 01/2012)|
|3.||Jacolot, Anne: 2 articles (06/2013 - 01/2012)|
|4.||Marchand, Sandrine: 2 articles (06/2013 - 01/2012)|
|5.||Louchahi, Kamel: 2 articles (06/2013 - 01/2012)|
|6.||Judel, Claire: 2 articles (06/2013 - 01/2012)|
|7.||Lin, Yi-Tsung: 1 article (08/2015)|
|8.||Fung, Chang-Phone: 1 article (08/2015)|
|9.||Pan, Yi-Jiun: 1 article (08/2015)|
|10.||Lin, Tzu-Lung: 1 article (08/2015)|
06/01/2013 - "How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinase-producing Enterobacter cloacae."
01/01/2012 - "Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae."
01/01/2011 - "In gram-negative bacteria, the resistance is mainly due to the rapid increase of extended-spectrum Beta-lactamases (ESBLs) in Klebsiella pneumonia, Escherichia coli, and Proteus species and high level third-generation cephalosporin Beta-lactamase resistance among Enterobacter spp. and Citrobacter spp., and multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species. "
01/01/2012 - "The aim of this study was to compare the bactericidal activity of cefepime plus amikacin against experimental pneumonia induced by a stably derepressed cephalosporinase-producing Enterobacter cloacae strain in immunocompetent and leucopenic rats. "
12/01/1998 - "The antibacterial activities of human regimens of cefepime, ceftazidime, and imipenem alone or in combination with amikacin against an isogenic pair of Enterobacter cloacae strains (wild type and its corresponding derepressed cephalosporinase mutant) were compared by using our nonlethal model of pneumonia with 180 immunocompetent rats. "
|2.||Cross Infection (Nosocomial Infection)
04/01/1996 - "The increasing prevalence of stable derepressed mutants over-producers of type I chromosomal cephalosporinase in inducible Enterobacteriaceae and Pseudomonas aeruginosa challenges the adequacy of third generation cephalosporins in the empirical treatment of certain nosocomial infections. "
05/01/1996 - "Nosocomial infections encountered in intensive care units are frequently due to Gram negative bacilli among which Stenotrophomonas maltophilia, Acinetobacter sp., and Enterobacter sp. The aim of the present study was to evaluate the in vitro bactericidal activity of the new broad spectrum cephalosporins cefepime (FEP) and cefpirome (CPO) alone or in combination with amikacin (AKN), gentamicin (GTN) or ciprofloxacin (CIP) against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae producing a derepressed cephalosporinase. "
02/01/1986 - "Reduction of cephamycin concentrations at the infection site in mice with experimental peritoneal infection caused by cephalosporinase-producing bacteria."
11/01/2014 - "The Gram-negative pathogenic bacteria Klebsiella oxytoca and Klebsiella pneumoniae produce the extended spectrum β-lactamase (ESBL) and cephalosporinase enzymes and are the major causes of hospital acquired (HA) infections and epidemics in non-hygienic communities in the majority of developing countries. "
05/01/2012 - "Therefore, ceftazidime may be recommended for the treatment of infections due to OXA-48 producers if they do not coproduce an extended-spectrum β-lactamase or a plasmid-mediated AmpC cephalosporinase."
09/01/1997 - "However, all isolates responsible for this type of infection at the University Hospital of Nancy from 1990 to 1994 (24 strains isolated from 22 patients presented an identical antibiotype with especially a natural resistance phenotype to beta-lactam antibiotics except one cephalosporinase-over-producing strain. "
10/01/2007 - "aeruginosa may accumulate intrinsic (overproduction of cephalosporinase AmpC, increased drug efflux, fluoroquinolone target mutations, and deficient production of porin OprD) and exogenous (production of secondary beta-lactamases and aminoglycoside-modifying enzymes) resistance mechanisms without losing its ability to generate severe bloodstream infections. "
01/01/1986 - "Amo1/R TicS CtnR strains (12%) were cephalosporinase producers and resistance to Amo/CA was observed, except for Proteus vulgaris. "
05/01/1988 - "aeruginosa: 1 ticarcillin, susceptible strain (TICs), 5 constitutive beta-lactamases producing strains (PSE, TEM, OXA1, OXA2, cephalosporinase (CEP). "
01/01/1986 - "AmoR TicR CtnR strains (18%) often produced two beta-lactamases (penicillinase and cephalosporinase) and they were resistant to Amo/CA; in this group, susceptibility to Tic/CA depends on the nature and the amount of the beta-lactamase produced, except for Serratia marcescens for which antibiotic resistance is probably due to other mechanisms. "
02/01/1985 - "The comparative in vitro activities of 12 antipseudomonal beta-lactams appreciated by microtiter MICs with an inoculum of 10(5) CFU were established according to phenotype: TIC-susceptible, TIC-R with a constitutive beta-lactamase (PSE-1, OXA-1, OXA-2, OXA-3, PSE-2 and a new type, TEM-1 and TEM-2 and derepressed cephalosporinase) or without detectable activity. "
|5.||Urinary Tract Infections (Urinary Tract Infection)
09/01/2012 - "Describe the presence of CTX-M-1 phylogenetic subgroup extended-spectrum β-lactamases (ESBL), associated with TEM and SHV genes, and the gene encoding cephalosporinase, CMY-2 in Escherichia coli and Klebsiella pneumoniae isolates from community-acquired urinary tract infections. "
09/01/1983 - "However, in a clinical trial of BRL 25000 (amoxicillin-clavulanic acid), excellent results were obtained in complicated urinary tract infections caused by Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii strains which produced cephalosporinase and were highly resistant to amoxicillin alone. "
|3.||Cephalosporins (Cephalosporin Antibiotics)
|7.||cefpirome (HR 810)
|9.||Anti-Bacterial Agents (Antibiotics)